Dendritic cell–related gene signature in pancreatic cancer stratifies patient subtypes and implicates a KCTD14–TNF signaling axis
We identified a novel DC-related gene signature that stratifies PC patients by prognosis and highlights KCTD14 as a novel immunomodulatory oncogene acting through the TNF-TNFR1 axis. Our findings provide a foundation for integrating DCRS into clinical risk assessment and for pursuing KCTD14/TNFR1-targeted therapies to overcome DC-mediated immune suppression in pancreatic cancer.
Authors
- Zhengwei Leng (ORCID: https://orcid.org/0000-0001-5740-7715)
- Yuheng Gu (ORCID: https://orcid.org/0000-0003-0209-3450)
- Yahui Chen (ORCID: https://orcid.org/0000-0002-8647-6856)
- Yuxin Liang (ORCID: https://orcid.org/0000-0001-6872-5030)
- Yuhao Su
- Deyuan Zhong
- Zilong Zhang (ORCID: https://orcid.org/0000-0002-4934-1258)
- Fei Wang (ORCID: https://orcid.org/0000-0001-8432-0009)
- Hongtao Yan
- Xiaolun Huang (ORCID: https://orcid.org/0000-0002-4993-0802)
Institutions
- Southwest Medical University (CN)
- Sichuan Cancer Hospital (CN)
- Chengdu Institute of Biology (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1665906
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05